$REGN News

Regeneron agrees to $270m extension to supply Ebola medicine in US

Regeneron Pharmaceuticals (REGN) Posts Nearly Four Years Of Survival Benefit Data For Libtayo

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Regeneron Pharma Extends Agreement With BARDA, Part Of ASPR Within US Department Of HHS, To Provide Additional Supply Of Inmazeb For US Preparedness Against Ebola Disease

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $980

Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results

Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

Regeneron Pharma Says EMA’s CHMP Adopts Positive Opinion Recommending Approval Of Alternative Dosing Schedule For Libtayo Across All Approved Indications

Did Earnings Beat Just Shift Regeneron Stock Investment Narrative?

Regeneron Pharmaceuticals (REGN) Reports 84 Week Phase III Efficacy For FOP Treatment

Regeneron Pharmaceuticals (REGN) Rallies On Earnings Beat As Undervalued Narrative Holds

Regeneron (REGN) Stock Still Looks Below Fair Value On Fresh Trial Data

UBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978

Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

What to Expect From Regeneron Pharmaceuticals' Next Quarterly Earnings Report

Regeneron reports 84-week Phase III data for Pasatru in adult FOP

Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month

Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension